Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Shelina Ramnarine, PhD
John Mascarenhas, MD
Marina Kremyanskaya, MD
Gastric Cancer Prevention: A Risk-Based Approach
Peter Buch, MD, FACG, AGAF, FACP
Chul Hyun, MD, PhD, MPH
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Charles Turck, PharmD, BCPS, BCCCP
Douglas A. Tremblay, MD
Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Steve Jackson, PharmD
Apar Kishor Ganti, MD
Thomas Marron, MD, PhD
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Amer Zeidan, MBBS
Ghayas Issa, MD
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD
Ritu Salani, MD
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
Treatment Decisions That Matter: A Case-Based Discussion in Advanced Ovarian Cancer
Axatilimab’s Impact on cGVHD and Associated BOS
Amandeep Salhotra, MD
Real-World Outcomes with Axatilimab in cGVHD
Brian P. McDonough, MD, FAAFP
Hana Safah, MD
The Art of Treatment Sequencing in Advanced Urothelial Carcinoma
Guru P. Sonpavde, MD
First-Line Treatment Considerations in Advanced Urothelial Carcinoma
Current Approaches to Advanced Urothelial Carcinoma
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.